Chu Besancon Hopital Jean Minjoz

Doubs 25030

0 studies enrolling now · 5 studies all time

What they study most

Advanced or Inoperable Gastric Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Gastric, or Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma (HCC)

Studies at this site

• A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) — Completed
• A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma — Completed
• Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma — Completed
• Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer — Completed
• A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma — Completed